BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs. 2001;61:777-787. [PMID: 11398909 DOI: 10.2165/00003495-200161060-00006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Postlethwaite D. Preconception Health Counseling for Women Exposed to Teratogens: The Role of the Nurse. Journal of Obstetric, Gynecologic & Neonatal Nursing 2003;32:523-32. [DOI: 10.1177/0884217503255373] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ranjan P, Athar M, Vijayakrishna K, Meena LK, Vasita R, Jha PC. Deciphering the anthelmintic activity of benzimidazolium salts by experimental and in-silico studies. Journal of Molecular Liquids 2018;268:156-68. [DOI: 10.1016/j.molliq.2018.07.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Garrido E, Van Domselaar M, Morales S, López-sanromán A. Enfermedad inflamatoria intestinal y gestación. Gastroenterología y Hepatología 2010;33:517-29. [DOI: 10.1016/j.gastrohep.2009.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Judge TA, Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology Clinics of North America 2004;33:421-54. [DOI: 10.1016/j.gtc.2004.03.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
5 Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012;54:28-33. [PMID: 21681114 DOI: 10.1097/mpg.0b013e318228349e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
6 Malhotra SV, Kumar V. A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids. Bioorganic & Medicinal Chemistry Letters 2010;20:581-5. [DOI: 10.1016/j.bmcl.2009.11.085] [Cited by in Crossref: 96] [Cited by in F6Publishing: 75] [Article Influence: 8.0] [Reference Citation Analysis]
7 Diamanti A, Capriati T, Papadatou B, Knafelz D, Bracci F, Corsetti T, Elia D, Torre G. The clinical implications of thalidomide in inflammatory bowel diseases. Expert Rev Clin Immunol. 2015;11:699-708. [PMID: 25865355 DOI: 10.1586/1744666x.2015.1027687] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
8 Prommer EE, Twycross R, Mihalyo M, Wilcock A. Thalidomide. Journal of Pain and Symptom Management 2011;41:140-5. [DOI: 10.1016/j.jpainsymman.2010.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Malhotra SV, Kumar V, Velez C, Zayas B. Imidazolium-derived ionic salts induce inhibition of cancerous cell growth through apoptosis. Med Chem Commun 2014;5:1404-9. [DOI: 10.1039/c4md00161c] [Cited by in Crossref: 27] [Article Influence: 3.4] [Reference Citation Analysis]
10 Lazzerini M, Villanacci V, Pellegrin MC, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Fontana M, Zuin G, Maggiore G, Bramuzzo M, Maschio M, Salemme M, Manenti S, Lorenzi L, Decorti G, Montico M, Ventura A. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017;15:1382-1389.e1. [PMID: 28286192 DOI: 10.1016/j.cgh.2017.02.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
11 Dalessandri D, Zotti F, Laffranchi L, Migliorati M, Isola G, Bonetti S, Visconti L. Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study. BMC Oral Health 2019;19:153. [PMID: 31311529 DOI: 10.1186/s12903-019-0850-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
12 Leite MR, Santos SS, Lyra AC, Mota J, Santana GO. Thalidomide induces mucosal healing in Crohn's disease: Case report. World J Gastroenterol 2011; 17(45): 5028-5031 [PMID: 22174554 DOI: 10.3748/wjg.v17.i45.5028] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
13 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Ranjan P, Athar M, Rather H, Vijayakrishna K, Vasita R, Jha PC. Rational design of imidazolium based salts as anthelmintic agents. Journal of Molecular Liquids 2018;255:578-88. [DOI: 10.1016/j.molliq.2018.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Carrión Valero F, Bertomeu González V. Toxicidad pulmonar por talidomida. Archivos de Bronconeumología 2002;38:492-4. [DOI: 10.1016/s0300-2896(02)75272-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:1079-1093. [PMID: 25858208 DOI: 10.1111/apt.13181] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
17 García-cabo C, Morís G. Peripheral neuropathy: An underreported neurologic manifestation of inflammatory bowel disease. European Journal of Internal Medicine 2015;26:468-75. [DOI: 10.1016/j.ejim.2015.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Bousvaros A. Thalidomide Treatment of Pediatric Ulcerative Colitis: A New Use for an Old Drug. Inflamm Bowel Dis. 2015;21:1750-1751. [PMID: 26199988 DOI: 10.1097/mib.0000000000000430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
19 Combe B. Thalidomide: new indications? Joint Bone Spine 2001;68:582-7. [DOI: 10.1016/s1297-319x(01)00326-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
20 Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn’s disease resistant to standard therapies. Aliment Pharmacol Ther. 2007;25:557-567. [PMID: 17305756 DOI: 10.1111/j.1365-2036.2006.03239.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]